Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

Lilly

Status and phase: Completed; Phase 2; Phase 1

Conditions: Malignant Pleural Mesotherioma

Treatments: Drug: Cisplatin; Drug: Pemetrexed

Study type: Interventional

Funder types: Industry

Identifiers

NCT00251550

H3E-JE-ME01

5249

Details and patient eligibility

About

To investigate efficacy and safety of pemetrexed combined with cisplatin for chemo-naive patients with Malignant Pleural Mesothelioma.

Sex: All

Ages: 20 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Inapplicable for radical operation
• Not received prior systemic chemotherapy
• Performance status: 0-1

Exclusion criteria

• Having a history of sensitivity to platinum agent, folic acid or vitamin B12

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)